Compile Data Set for Download or QSAR
Report error Found 684 Enz. Inhib. hit(s) with Target = 'Proprotein convertase subtilisin/kexin type 9/Low-density lipoprotein receptor'
LigandPNGBDBM586102(US11530244, Compound 004)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586103(US11530244, Compound 005)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586105(US11530244, Compound 007)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586108(US11530244, Compound 010)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586117(US11530244, Compound 034)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586118(US11530244, Compound 035)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586119(US11530244, Compound 036)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586121(US11530244, Compound 038)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586128(US11530244, Compound 046)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586133(US11530244, Compound 051)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586136(US11530244, Compound 054)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586140(US11530244, Compound 058)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586147(US11530244, Compound 065)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586148(US11530244, Compound 066)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586149(US11530244, Compound 067)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586150(US11530244, Compound 068)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586157(US11530244, Compound 130)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586164(US11530244, Compound 146)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586169(US11530244, Compound 152)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586175(US11530244, Compound 171)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586179(US11530244, Compound 184)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586180(US11530244, Compound 185)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586200(US11530244, Compound 223)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM50554744(CHEMBL4759663 | US11530244, Compound 248)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586214(US11530244, Compound 275)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586215(US11530244, Compound 276)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586216(US11530244, Compound 277)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586217(US11530244, Compound 281)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586223(US11530244, Compound 293)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586225(US11530244, Compound 296)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586236(US11530244, Compound 318)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586242(US11530244, Compound 327)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586243(US11530244, Compound 328)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586247(US11530244, Compound 332)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586251(US11530244, Compound 336)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586255(US11530244, Compound 340)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586258(US11530244, Compound 343)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586261(US11530244, Compound 346)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586263(US11530244, Compound 349)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586272(US11530244, Compound 358)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586273(US11530244, Compound 359)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586274(US11530244, Compound 360)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586275(US11530244, Compound 361)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586276(US11530244, Compound 362)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586277(US11530244, Compound 363)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586279(US11530244, Compound 365)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586280(US11530244, Compound 366)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586281(US11530244, Compound 367)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586283(US11530244, Compound 369)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

LigandPNGBDBM586284(US11530244, Compound 370)
Affinity DataIC50: 50nMAssay Description:A set of cyclic polypeptides were identified to inhibit the interaction between human PCSK9 and human LDLR. Each polypeptide has an N-terminal amino ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 684 total ) | Next | Last >>
Jump to: